Research programme: topoisomerase inhibitors - University of North Carolina School of Medicine/Unknown companyAlternative Names: Paternal UBE3A gene expression stimulant; UBE3A protein stimulants
Latest Information Update: 21 Feb 2015
At a glance
- Originator Unknown
- Developer University of North Carolina at Chapel Hill School of Medicine; Unknown
- Mechanism of Action DNA topoisomerase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Angelman syndrome
Most Recent Events
- 01 Oct 2013 Early research in Angelman syndrome in USA (unspecified route)